134 related articles for article (PubMed ID: 36468686)
1. Maytansinol Functionalization: Towards Useful Probes for Studying Microtubule Dynamics.
Boiarska Z; Pérez-Peña H; Abel AC; Marzullo P; Álvarez-Bernad B; Bonato F; Santini B; Horvath D; Lucena-Agell D; Vasile F; Sironi M; Díaz JF; Prota AE; Pieraccini S; Passarella D
Chemistry; 2023 Jan; 29(5):e202203431. PubMed ID: 36468686
[TBL] [Abstract][Full Text] [Related]
2. Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders.
Marzullo P; Boiarska Z; Pérez-Peña H; Abel AC; Álvarez-Bernad B; Lucena-Agell D; Vasile F; Sironi M; Altmann KH; Prota AE; Díaz JF; Pieraccini S; Passarella D
Chemistry; 2022 Jan; 28(2):e202103520. PubMed ID: 34788896
[TBL] [Abstract][Full Text] [Related]
3. Antitubulin activities of ansamitocins and maytansinoids.
Ikeyama S; Takeuchi M
Biochem Pharmacol; 1981 Sep; 30(17):2421-5. PubMed ID: 21043240
[TBL] [Abstract][Full Text] [Related]
4. C3 ester side chain plays a pivotal role in the antitumor activity of Maytansinoids.
Li W; Huang M; Li Y; Xia A; Tan L; Zhang Z; Wang Y; Yang J
Biochem Biophys Res Commun; 2021 Aug; 566():197-203. PubMed ID: 34144258
[TBL] [Abstract][Full Text] [Related]
5. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.
Lopus M; Oroudjev E; Wilson L; Wilhelm S; Widdison W; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2689-99. PubMed ID: 20937594
[TBL] [Abstract][Full Text] [Related]
6. Maytansinol Functionalization: Towards Useful Probes for Studying Microtubule Dynamics.
Boiarska Z; Pérez-Peña H; Abel AC; Marzullo P; Álvarez-Bernad B; Bonato F; Santini B; Horvath D; Lucena-Agell D; Vasile F; Sironi M; Díaz JF; Prota AE; Pieraccini S; Passarella D
Chemistry; 2023 Jan; 29(5):e202300069. PubMed ID: 36692211
[TBL] [Abstract][Full Text] [Related]
7. High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.
Goldmacher VS; Audette CA; Guan Y; Sidhom EH; Shah JV; Whiteman KR; Kovtun YV
PLoS One; 2015; 10(2):e0117523. PubMed ID: 25671541
[TBL] [Abstract][Full Text] [Related]
8. A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin.
Menchon G; Prota AE; Lucena-Agell D; Bucher P; Jansen R; Irschik H; Müller R; Paterson I; Díaz JF; Altmann KH; Steinmetz MO
Nat Commun; 2018 May; 9(1):2106. PubMed ID: 29844393
[TBL] [Abstract][Full Text] [Related]
9. New insights into the anticancer therapeutic potential of maytansine and its derivatives.
Zafar S; Armaghan M; Khan K; Hassan N; Sharifi-Rad J; Habtemariam S; Kieliszek M; Butnariu M; Bagiu IC; Bagiu RV; Cho WC
Biomed Pharmacother; 2023 Sep; 165():115039. PubMed ID: 37364476
[TBL] [Abstract][Full Text] [Related]
10. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.
Oroudjev E; Lopus M; Wilson L; Audette C; Provenzano C; Erickson H; Kovtun Y; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2700-13. PubMed ID: 20937595
[TBL] [Abstract][Full Text] [Related]
11. A fluorescent probe and a photoaffinity labeling reagent to study the binding site of maytansine and rhizoxin on tubulin.
Sawada T; Kato Y; Kobayashi H; Hashimoto Y; Watanabe T; Sugiyama Y; Iwasaki S
Bioconjug Chem; 1993; 4(4):284-9. PubMed ID: 8218485
[TBL] [Abstract][Full Text] [Related]
12. Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy.
Cao S; Dong YH; Wang DF; Liu ZP
Curr Med Chem; 2020; 27(27):4567-4576. PubMed ID: 32175831
[TBL] [Abstract][Full Text] [Related]
13. Modeling the effects of drug binding on the dynamic instability of microtubules.
Hinow P; Rezania V; Lopus M; Jordan MA; Tuszyński JA
Phys Biol; 2011 Oct; 8(5):056004. PubMed ID: 21836336
[TBL] [Abstract][Full Text] [Related]
14. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids.
Kupchan SM; Sneden AT; Branfman AR; Howie GA; Rebhun LI; McIvor WE; Wang RW; Schnaitman TC
J Med Chem; 1978 Jan; 21(1):31-7. PubMed ID: 563462
[TBL] [Abstract][Full Text] [Related]
15. Antibody-DM1 conjugates as cancer therapeutics.
Lopus M
Cancer Lett; 2011 Aug; 307(2):113-8. PubMed ID: 21481526
[TBL] [Abstract][Full Text] [Related]
16. Constitutive overexpression of asm18 increases the production and diversity of maytansinoids in Actinosynnema pretiosum.
Li S; Lu C; Chang X; Shen Y
Appl Microbiol Biotechnol; 2016 Mar; 100(6):2641-9. PubMed ID: 26572523
[TBL] [Abstract][Full Text] [Related]
17. Rhizoxin binding to tubulin at the maytansine-binding site.
Takahashi M; Iwasaki S; Kobayashi H; Okuda S; Murai T; Sato Y
Biochim Biophys Acta; 1987 Dec; 926(3):215-23. PubMed ID: 3120782
[TBL] [Abstract][Full Text] [Related]
18. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.
Bai RL; Paull KD; Herald CL; Malspeis L; Pettit GR; Hamel E
J Biol Chem; 1991 Aug; 266(24):15882-9. PubMed ID: 1874739
[TBL] [Abstract][Full Text] [Related]
19. Antibody drug conjugates of cleavable amino-benzoyl-maytansinoids.
Nittoli T; Delfino F; Kelly M; Carosso S; Markotan T; Kunz A; Chen Z; Mao S; Shan J; Navarro E; Zhao F; Makonnen S; Hickey C; Spink J; Olson W; Kirshner JR; Thurston G; Papadopoulos N
Bioorg Med Chem; 2020 Dec; 28(23):115785. PubMed ID: 33099182
[TBL] [Abstract][Full Text] [Related]
20. Megakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division.
Yang H; Ganguly A; Yin S; Cabral F
Cytoskeleton (Hoboken); 2011 Mar; 68(3):175-87. PubMed ID: 21309084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
